The major advances in acute promyelocytic leukemia treatment are targeted drugs that attack the disease’s genetic driver directly. All-trans retinoic acid (ATRA) combined with arsenic trioxide (ATO) now cures most patients with lower-risk disease without conventional chemotherapy, and high-risk patients do very well when a limited amount of chemotherapy is added. The biggest remaining danger is bleeding in the first days, which is why treatment starts the moment the diagnosis is suspected.
A few decades ago, acute promyelocytic leukemia (APL) was among the most rapidly fatal leukemias. Today it is one of the most curable. This guide explains why, what modern treatment looks like in practice, and what patients can expect.
What Makes APL Different From Other Leukemias?
APL is a subtype of acute myeloid leukemia (AML). Immature white cells called promyelocytes build up in the bone marrow because they are stuck and cannot mature into normal neutrophils.
The cause is a swap of genetic material between chromosomes 15 and 17, written as t(15;17). This joins two genes, PML and RARA, into a single PML-RARA fusion gene. The fusion protein blocks the normal signal that tells promyelocytes to mature.
The exact reason the translocation happens is usually unknown. Most people with APL have no identifiable trigger, although a small number of cases follow earlier chemotherapy or radiation for another cancer. Our overview of promyelocytic leukemia causes and diagnosis covers this background in more detail.
Like other hematologic cancers, APL disrupts normal blood production. What sets it apart is that its driver is a single, well-defined target. That is very different from leukemias such as Philadelphia chromosome-positive ALL, which has its own fusion gene and its own targeted drugs. For a wider view of how leukemias are approached, see our guide to navigating leukemia from diagnosis to treatment.
Symptoms and the Bleeding Emergency
APL often comes on over days to weeks. The abnormal promyelocytes crowd out normal blood cells, causing:
- Easy bruising, nosebleeds, bleeding gums, and petechiae (tiny red spots under the skin)
- Heavy menstrual bleeding or blood in the urine
- Tiredness and breathlessness from anemia and fatigue
- Fevers and infections from a lack of working white cells
The key danger is coagulopathy. APL cells release substances that switch on clotting and clot breakdown at the same time, a picture similar to disseminated intravascular coagulation (DIC). Clotting factors and fibrinogen are used up, and serious bleeding, including bleeding in the brain, can occur. This is why APL is treated as a medical emergency.
How APL Is Diagnosed
Diagnosis combines a look at the cells with tests for the genetic driver.
- Blood count and blood film: often low platelets and hemoglobin; abnormal promyelocytes with dense granules and sometimes bundles of rod-shaped Auer rods
- Clotting tests: prolonged PT, low fibrinogen, and raised D-dimer point to coagulopathy
- Bone marrow aspirate and biopsy: confirms the leukemia and its extent
- FISH or RT-PCR: detects t(15;17) and the PML-RARA fusion, confirming APL
In my practice, if the blood film looks like APL, ATRA is started straight away, before genetic confirmation. Waiting for results costs time that the clotting system cannot afford.
Modern Acute Promyelocytic Leukemia Treatment
Modern APL leukemia treatment is divided into phases. Induction aims to clear the leukemia from the marrow and correct the clotting disorder. Consolidation then mops up remaining disease, and some regimens add a period of maintenance. Treatment is shaped by the white cell count at diagnosis, which is the main risk marker.
| Risk group | White cell count at diagnosis | Usual first-line approach |
|---|---|---|
| Low / intermediate risk | 10 × 10⁹/L or less | ATRA plus arsenic trioxide, no conventional chemotherapy |
| High risk | Above 10 × 10⁹/L | ATRA plus arsenic trioxide with added chemotherapy (such as an anthracycline), or ATRA plus chemotherapy |
Advance 1: ATRA, a differentiation therapy
ATRA is a form of vitamin A. At treatment doses it overrides the PML-RARA block so leukemic promyelocytes mature into normal-looking cells and die off naturally. It also corrects the clotting disorder quickly, which is why it is started early.
Advance 2: Arsenic trioxide
Arsenic trioxide causes the PML-RARA fusion protein to be broken down, pushing leukemic cells to mature and die. First used for relapsed disease, it is now part of standard first-line treatment.
Advance 3: Chemotherapy-free treatment
Combining ATRA and ATO has allowed many patients with lower-risk disease to avoid conventional chemotherapy. This means less hair loss, fewer severe infections, and a lower risk of later heart damage from anthracyclines.
Advance 4: Intensive supportive care
Much of the early improvement in survival comes from aggressive support in the first weeks. Platelet transfusions, fibrinogen replacement with cryoprecipitate, and fresh frozen plasma are given to keep clotting tests in a safer range until the coagulopathy resolves.
Advance 5: Molecular monitoring
Sensitive RT-PCR testing for PML-RARA after treatment shows whether any leukemia remains at a molecular level. Rising signals can prompt early treatment before a full relapse.
Side Effects to Know About
- Differentiation syndrome: as cells mature, some patients develop fever, breathlessness, fluid build-up, weight gain, and low blood pressure. It is treated promptly with steroids and sometimes by pausing ATRA or ATO.
- QT prolongation: arsenic can affect the heart’s electrical rhythm, so ECGs are checked regularly and potassium and magnesium are kept in the normal range.
- Headache and raised pressure around the brain: a recognized side effect of ATRA.
- Liver test changes: both drugs can raise liver enzymes, which are monitored.
When to See a Doctor
APL is rare, but its warning signs overlap with many common problems. Seek urgent medical care if you notice unexplained bruising or tiny red spots on the skin, bleeding that is hard to stop, blood in the urine, or unusual tiredness together with fevers. A simple blood count can quickly show whether further tests are needed.
If you are already on treatment, report any new breathlessness, swelling, rapid weight gain, fever, palpitations, or severe headache straight away. These can be early signs of differentiation syndrome or other treatment effects that respond well when caught early.
Key Takeaways
- APL is driven by the PML-RARA fusion from t(15;17), a single, targetable abnormality.
- ATRA and arsenic trioxide have made APL one of the most curable leukemias.
- Many lower-risk patients are now treated without conventional chemotherapy.
- Bleeding in the first days is the main threat, so treatment and supportive care start immediately.
- Relapse is uncommon, and molecular testing helps catch it early.
Frequently Asked Questions
Is acute promyelocytic leukemia curable?
Yes. With modern ATRA and arsenic-based treatment, most patients who get through the first weeks are cured. The greatest risk lies in early bleeding, which is why fast diagnosis and treatment matter so much.
Is arsenic trioxide safe to use as a medicine?
Arsenic trioxide is given in carefully controlled doses under close monitoring. Its main risks, such as heart rhythm changes and differentiation syndrome, are well known and managed with regular ECGs, blood tests, and prompt treatment.
How long does APL treatment last?
Treatment usually runs over several months, covering induction and then consolidation cycles. Some regimens also include a maintenance phase, depending on the approach used and the patient’s risk group.
Can APL come back after treatment?
Relapse is uncommon with current treatment, especially in lower-risk disease. If it does return, arsenic-based therapy and stem cell transplant can still achieve a lasting remission for many patients.
